Artificial Intelligence as an Inventor in Pharmaceutical Patents: Analysis of the DABUS Cases and Their Implications for Drug Development

Abstract

The use of artificial intelligence (AI) as an inventor in pharmaceutical patents is a rapidly evolving area, with significant implications for the pharmaceutical industry and regulatory bodies. The DABUS cases have highlighted the need for clear guidelines and regulations on the use of AI in patent applications, as well as the importance of transparency and accountability in the use of AI in the inventive process. This thesis provides an analysis of the DABUS cases and their implications for drug development, including the potential for AI to drive innovation and growth in the pharmaceutical industry. The thesis also provides recommendations for regulatory bodies, the pharmaceutical industry, and patent offices, and highlights the need for further research and development in the area of AI-generated inventions.